Mother-of-two, 49, issues warning after weight loss jabs left her passing BLACK urine and hospitalised: 'I thought I was going to die'
Claire Reed, from Aberdeen in Scotland, was prescribed Mounjaro in March after she was left 'fed up' of not fitting into her clothes properly.
The 49-year-old, who was classed as overweight, claimed she only had to fill out a questionnaire provided by online pharmacy MedExpress before she was offered the £200 a month drug.
She lost four stone in the first four months, dropping from 15 to 11 stone.
But in June, she suddenly began to feel nauseous every time she tried to eat or drink and would faint almost daily.
Despite noticing her urine had turned black due to dehydration she refused to tell family and friends she was on the jab over fear of embarrassment.
It was only when she fell unconscious in the car, her son and daughter rushed her to hospital and she was immediately put on an IV drip to rehydrate the body.
Tirzepatide, the ingredient behind Mounjaro, has long been hailed a game-changer in tackling obesity.
Administered weekly, the drug—manufactured by Eli Lilly—is designed to help type 2 diabetes patients control their blood sugar levels or for obese people to lose weight for health purposes
Administered weekly, the drug—manufactured by Eli Lilly—is designed to help type 2 diabetes patients control their blood sugar levels or for obese people to lose weight for health purposes.
However, the injections, known collectively as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are known to cause worrying side effects such as pancreatitis—when the pancreas suddenly becomes inflamed—or gastrointestinal issues.
The family of drugs known as GLP-1 RAs, originally developed to treat diabetes, are now often being used for weight loss as they were found to suppress a patient's appetite.
Recalling her terrifying ordeal, Ms Reed said: 'I was going on holiday to Dubai with my daughter and I was fed up with not fitting in my clothes. I wasn't really that big but that was the motivation to start.
'I ordered them online, I didn't go to the doctor. There were no instructions on how to deal with it, it works for a lot of women quite well.
'I couldn't eat so I was just collapsing because I had no food or water, I wasn't able to process anything in my body.
'I felt very sick and had no appetite. Even on holiday, I couldn't eat. It's not nice going on holiday and not eating because your whole life revolves around food.
'I kept collapsing at the end of the day because when you're not drinking or eating anything your body just shuts down.
'It was always at the end of the day but I didn't say anything, I was embarrassed.
'I was never going to the toilet and when I did my urine was black. I had to force myself to drink water.'
She added: 'We were in the car and I was just passing out, going in and out of consciousness, my daughter and son started panicking and they took me straight to the doctor, who referred me to hospital.
'They put me on an IV. I told them I've been taking the jab and they said this could be what it is.'
Ms Reed has now vowed never to use the jabs again but is still struggling to eat as she did before starting the medication.
'I'm still not hungry and still not gaining weight. Any food at all makes me feel sick,' she said.
'I was very scared, your body needs food and fluid. I thought I could die, I stopped just now and I've never been like this before, trying to get the jab out of my system.
'The consultant said this is a big problem because the people selling it to you can't see you, they're just asking a quick questionnaire. And then you're left on your own.
'Your appetite won't come back, it's absolutely terrible. I'm so weak and tired all the time.
'There's not enough awareness about the dangers of taking it, everyone wants to lose weight and feel great but there are risks.'
MedExpress and Eli Lilly have both been approached for comment.
At least half a million NHS patients and some 15million patients in the US are now thought to be using weight-loss jabs, which can help patients lose up to 20 per cent of their body weight in just a few months.
And the numbers using them privately are even higher.
They have also been shown to significantly reduce the risk of heart attacks and strokes.
However, other reported problems using the jabs include constipation, fatigue, headaches, dizziness and even hair loss.
In June, UK medicines watchdog the Medicines and Healthcare products Regulatory Agency (MHRA) also revealed it had received more than 560 reports of people developing an inflamed pancreas after taking so-called 'GLP-1' injections since they were first launched. Ten cases proved fatal.
Under official guidelines, only patients who have a body mass index (BMI) of over 35 and at least one weight-related health problem like high blood pressure, or those who have a BMI of 30 to 34.9 and meet the criteria for referral to a specialist weight management service, should be prescribed weight loss jabs.
In the UK, law forbids the sale of such drugs without a prescription from a medical professional.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
27 minutes ago
- The Independent
New weight loss pill more ‘tolerable' than jabs shown to be effective in key trial
A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed kilos in weeks. Its release will offer people with obesity a new and convenient alternative to jabs. Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched. Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron. The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite. The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs. Weight loss jabs have been hailed as transformative by health leaders. But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight. The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug. Three in five (60 per cent) of people taking the highest dose of orforglipron lost at least 10 per cent of their body weight, while 40 per cent lost at least 15 per cent of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025. In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk. Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect. The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes. 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10 per cent weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. 'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.' It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists. They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight. The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine. Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse. But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder. 'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote. 'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders. 'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.'
The Guardian
28 minutes ago
- The Guardian
David Brooks obituary
My former husband David Brooks, who has died aged 86, was a GP in Manchester across four decades, and a trainer of GPs in the city for many of those years. In addition David advised law firms on legal and medical matters, was a police doctor on custody cases and provided medical advice to the Library theatre company in Manchester for some of their productions, also giving flu jabs to actors before their Christmas productions. For some years he dispensed medical advice to callers on Natalie Anglesey's Radio Manchester programme. He was born in Hyde, Manchester, to parents of Irish descent, Jim, a railway guard, and Helen (nee Blake), who ran a tripe shop. After attending De la Salle grammar school in Salford he went on to study medicine at Manchester University. In 1964, having become a doctor, David started out as a GP at the Peterloo Medical Centre in Middleton, Manchester, where he remained until his retirement in 1999. In the course of his career he was appointed regional adviser for GP training for the Manchester regional health district, and he was also responsible for the academic training of GP trainers. With other trainers he frequently visited Kuwait, at the invitation of the government there, to help improve the standard of GP work throughout the country. He also toured India, examining standards in medical schools and writing many excellent articles about India and Indian medicine. His thoughts on general practice were published in various medical journals, including in the Lancet, and for some years he was on the editorial board of the clinical journal Update. He was involved in the foundation of the GP Writers Association, which later became the Society of Medical Writers. David and I met in 1989, and remained friends after an amicable divorce in 2001. A man with a big heart, he had a quality of kindness and decency that endeared him to all those who met him. David is survived by his third wife, Diane, by five children, Stephen, Helen, Sarah, Jane and Phillip, from his first marriage, to Brenda, which ended in divorce, six stepchildren from his second and third marriages, and nine grandchildren.
Daily Mail
28 minutes ago
- Daily Mail
Kenny Logan bravely reveals his sex life struggles with wife Gabby (and what he keeps private in the bedroom) after he had his prostate removed following cancer battle
Kenny Logan has bravely revealed his sex life struggles with wife Gabby to raise awareness for men who have also had their prostate removed. Former Scottish rugby international Kenny, 53, was diagnosed with cancer in February 2022 after Gabby, 52, urged him to go to the doctors. In a candid chat with the Telegraph, Kenny shared erections became 'impossible' during his cancer battle which he feared would take a toll on their sex life. He said: 'I was forewarned that prostatectomy meant that, at least for a while, getting erections would be impossible. That's a huge deal for any man.' 'I never allowed myself to stress "what if they never come back". Instead, I focused on being fit and cancer-free, I'm relentlessly positive. After about three months, I was relieved to have some movement down there. 'When it came to sex, things were 'inconsistent' let's say, for a good three months [after that].' Kenny also explained he used a 'penis pump' to to stimulate an erection, which he insists on keeping private in the bedroom. Vacuum pumps encourage blood to flow to the penis, causing an erection. They work for most men and can be used if medicine is not suitable or does not work, as per the NHS. He said: 'It's certainly not sexy... I used it for 10 minutes a day or so, several times in that first month, grateful Gabby was away working on the Commonwealth Games. 'I warned her that if she ever walked in on me using it and didn't back straight out the door, I'd never speak to her again! Some things are private, even in marriage.' Kenny and presenter Gabby have been married for over 22 years and share two children together. In February 2023, Kenny spoke candidly about the after-effects of treatment, and said they left him 'black and blue downstairs'. Speaking to The Telegraph at the time, he said: 'Whether it be my dyslexia, my relationship, IVF, we've always been quite open. So, I was quite happy to talk about erectile dysfunction and all these other things because I was like, "It is a symptom".' 'From a sexual point of view, it's not consistent. As the surgeon said to me, this could take 18 months. 'Within a month, I was getting movement, where he says, "That's amazing". So it's just not as consistent. The beauty is you can take a tablet and it changes things.' He explained that his brave honesty was motivated by his desire to help other people. Reiterating the need for all men his age to get checked, he said: 'If I can help one person, that'd be great. But I've probably helped a lot of people with the coverage it had.' The couple said Kenny was 'extremely lucky' they caught it early, which afforded him options regarding treatment. Kenny was inspired to go for a general check up after hearing guests on his wife's podcast discuss having their hormones tested. And when he did his results showed a high level of PSA - prostate-specific antigen. 'I got checked and very quickly, within three to four months, I had a biopsy and they said there was something there but they'd keep an eye on it,' he said. He said what stood out the most from that appointment was the specialist telling him '40 per cent of [his] mates have got this [high PSA levels] but don't know'. It doesn't always lead to cancer and many men go their entire lives not knowing. So when he was diagnosed with prostate cancer a short time later, Kenny recalled it being 'a huge shock'. He made the decision to remove the prostate entirely and is now three months post operation feeling almost as good as new. 'I'm probably about 90 per cent back to normal,' he said. Prostate cancer can often be treated if caught early, but symptoms usually do not show up until the cancer is already in advanced states. It is the most common cancer in men in the UK. The couple are encouraging men to learn more about the disease and consider talking to their GP about the risks. Every year, upwards of 52,300 men are diagnosed with prostate cancer in the UK - more than 140 every day. Up to 11,800 men in Britain die from prostate cancer annually, meaning it trails only lung and bowel cancer in yearly fatalities. WHAT IS PROSTATE CANCER? How many people does it kill? More than 11,800 men a year - or one every 45 minutes - are killed by the disease in Britain, compared with about 11,400 women dying of breast cancer. It means prostate cancer is behind only lung and bowel in terms of how many people it kills in Britain. In the US, the disease kills 26,000 men each year. Despite this, it receives less than half the research funding of breast cancer and treatments for the disease are trailing at least a decade behind. How many men are diagnosed annually? Every year, upwards of 52,300 men are diagnosed with prostate cancer in the UK - more than 140 every day. How quickly does it develop? Prostate cancer usually develops slowly, so there may be no signs someone has it for many years, according to the NHS. If the cancer is at an early stage and not causing symptoms, a policy of 'watchful waiting' or 'active surveillance' may be adopted. Some patients can be cured if the disease is treated in the early stages. But if it is diagnosed at a later stage, when it has spread, then it becomes terminal and treatment revolves around relieving symptoms. Thousands of men are put off seeking a diagnosis because of the known side effects from treatment, including erectile dysfunction. Tests and treatment Tests for prostate cancer are haphazard, with accurate tools only just beginning to emerge. There is no national prostate screening programme as for years the tests have been too inaccurate. Doctors struggle to distinguish between aggressive and less serious tumours, making it hard to decide on treatment. Men over 50 are eligible for a 'PSA' blood test which gives doctors a rough idea of whether a patient is at risk. But it is unreliable. Patients who get a positive result are usually given a biopsy which is also not fool-proof. Scientists are unsure as to what causes prostate cancer, but age, obesity and a lack of exercise are known risks. Anyone with any concerns can speak to Prostate Cancer UK's specialist nurses on 0800 074 8383 or visit
